Nectar Lifesciences Limited Financial Ratios
NECLIFE · Healthcare · Current price ₹10.54
P/E ratio
-0.9x
P/B ratio
0.4x
ROE
-50.3%
ROCE
-8.9%
Debt / Equity
0.00
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | -0.9x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 0.4x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | -50.3% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -8.9% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.00 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Nectar Lifesciences Limited's latest numbers.
Nectar Lifesciences Limited profitability
Nectar Lifesciences Limited generates a return on equity of -50.3% and a return on capital employed of -8.9%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.00 and a P/E of -0.9x, Nectar Lifesciences Limited is conservatively financed. Our overall business-quality score for the company is 3.5 / 10.
Understand the ratios
More on Nectar Lifesciences Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.